mbiomics GmbH

We are proud to be part of this initiative. It's an important step for the #microbiome industry. Kudos Herve Affagard, MBA, Eng. Nikole Kimes 🚀 for making it happen.

Important new data from ESMO 2024: Ciccarese et al. report here that fecal microbiota transplant (FMT) improves first-line therapy efficacy in patients with metastatic renal cell carcinoma. In this RCT, FMT increases 1-year progression-free survival from 35% in the placebo group receiving anti-PD-1/PD-L1 + VEGFR-TKIs to 66.7% in patients receiving FMT+ PD-1/PD-L1 +VEGFR-TKIs. This spectacular data further supports the opportunities to significantly improve patient outcomes in IO with microbiome-modulating therapies.

If you want to learn more about mbiomics GmbH’s unique techbio approach to next-gen #microbiome-based therapeutics, read the latest feature article in Plattform Life Sciences: https://bit.ly/3MA7gR3. Our fully synthetic complex consortia products that recapitulate healthy microbiomes “supercharged” with indication-/MoA-specific strains bear potential to change the treatment paradigm in many high-value indications where strong clinical evidence exists from fecal microbiome transplants (FMTs). By comprehensive integration of innovative enabling technologies, we are designing and manufacturing a pipeline of modular therapeutic products with accelerated path into the clinic. Thank you Urs Moesenfechtel for the great case study and highlighting our innovative complex consortia strategy to unlock the full potential of the microbiome for the safe and effective treatment of in indications with a high unmet clinical need.

Thrilled to announce that mbiomics GmbH has been selected as a finalist to pitch at the BARDAVITAL Global Health Security Symposium on June 27 in Berlin - we are honored to be part of it. Join our CEO Laura Figulla and watch her showcase our novel approach to microbiome-based therapeutics designed to access the full potential of the microbiome and to change the treatment paradigm in many chronic diseases. This event focuses on visionary advancements in therapeutics innovation, and medical countermeasures aimed at enhancing pandemic preparedness and response for a safer future. Register now ➡️ https://lnkd.in/dH4BWcKF Be a part of the future of healthcare innovation — we hope to see you there! #DigitalHealth #Vaccines #Therapeutics #GlobalHealth #Biotech @Biomedical Advanced Research and Development Authority (BARDA) @VITAL – A BARDA BAN Hub

This week, our CSO, Christopher Weidenmaier and our CTO, Johannes B. Woehrstein provided their industry insights as part of European Pharmaceutical Review #microbiome series. Chris and Jo highlighted the current challenges and opportunities in the development and manufacturing of next-generation live biotherapeutic products (#LBPs), which harbor a great therapeutic potential in a variety of indications, including #cancer. Read the full article here https://bit.ly/4bwYOwd and learn more about our company’s proprietary #techbio platform that aims to combine the disease-modifying potential of large consortia with the safety and scalable manufacturability of GMP-manufactured non-engineered microbial strains at www.mbiomics.com

Our CEO and Co-founder, Laura Figulla, was recently featured in Drug Target Review's “Women in STEM” series, speaking about her experiences as a life science entrepreneur and what needs to be done to further support #GenderEquality in our sector. At mbiomics GmbH, a central goal in our corporate culture is to provide an inclusive work environment, and we are proud that these efforts are reflected by the fact that more than 50% of our R&D team members are women! 🚀 🚀 🚀 🚀 Read the full article here https://bit.ly/4a4sgsq and learn more about our company’s novel techbio approach to unlock the full potential of the #microbiome to overcome severe and chronic diseases at www.mbiomics.com #WomenInSTEM

The #Microbiome just got some very neat coverage by the The Economist. As a long-term Econnmist reader, I was pretty excited about the microbiome therapeutics article published late 2023. Having one of the best podcasts out there cover a topic I am super excited about is absolutely fantastic.

It’s exciting to see the innovation in the #microbiome field getting some well-deserved attention in last week's episode of The Economist's science & technology #podcast “Babbage”. Gilead Amit did a great job summarizing the challenges of current microbiome-based therapeutic interventions and discussing ways to tackle them. We share the view that we need to move beyond the limitations of current state-of-the-art treatments and use the newest technologies to provide reliable and reproducible therapies for patients with severe and chronic indications. As part of this transformative field, we at mbiomics design and develop a novel class of complex live biotherapeutic products that recapitulate the functional diversity and activity of healthy microbiomes to overcome disease.   Listen to the full episode https://lnkd.in/ey2NeaSi and learn more about our novel #techbio platform approach at www.mbiomics.com.

mbiomics GmbH continues to grow in 2024! Exciting Opportunity in Microbiome Therapeutics Development! We're seeking Bioinformatics and Computational Biology experts to drive cutting-edge drug discovery. Passionate about #microbiome #innovation? We're always open to applications from scientists eager to be at the forefront of this dynamic industry. Apply now and shape the future with us! #Biotech #Microbiome #Innovation #ScienceCareers #JoinOurTeam https://lnkd.in/dARbtn_m